Vascular Medicine

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Register here to gain access to SAGE's 500+ Journals Online

Sign In to gain access to subscriptions and/or personal tools.
This Article
Right arrow Abstract Freely available
Right arrow Free Full Text (Free PDF) Free
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kelly, A. S.
Right arrow Articles by Bank, A. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kelly, A. S.
Right arrow Articles by Bank, A. J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?
Vascular Medicine, Vol. 12, No. 4, 311-318 (2007)
DOI: 10.1177/1358863X07084200

Rosiglitazone improves endothelial function and inflammation but not asymmetric dimethylarginine or oxidative stress in patients with type 2 diabetes mellitus

Aaron S. Kelly

Department of Research, St Paul Heart Clinic, St Paul, MN, USA, School of Medicine, University of Minnesota, Minneapolis, MN, USA, kelly105{at}umn.edu

Andrea M. Thelen

Department of Research, St Paul Heart Clinic, St Paul, MN, USA

Daniel R. Kaiser

School of Medicine, University of Minnesota, Minneapolis, MN, USA

J. Michael Gonzalez-Campoy

Minnesota Center for Obesity, Metabolism and Endocrinology, Eagan, MN, USA

Alan J. Bank

Department of Research, St Paul Heart Clinic, St Paul, MN, USA, School of Medicine, University of Minnesota, Minneapolis, MN, USA

We compared the vascular effects of rosiglitazone versus glyburide and evaluated asymmetric dimethylarginine (ADMA) and oxidative stress as potential mechanisms associated with changes in vascular health in patients with type 2 diabetes mellitus (T2DM). Patients were randomized to 6 months of either rosiglitazone (n = 20) or glyburide (n = 16) in addition to metformin. The following variables were measured pre- and post-treatment: glucose, insulin, homeostasis model assessment (HOMA), hemoglobin A1c (HbA1c), C-peptide, blood pressure, lipids, C-reactive protein (CRP), ADMA, 8-isoprostane, oxidized LDL cholesterol, brachial artery flow-mediated dilation (FMD), endothelium-independent dilation (EID), and brachial and carotid artery stiffness. Rosiglitazone and glyburide treatment resulted in significant and equivalent decreases in glucose (p < 0.0001) and HbA1c (p < 0.0001), with a trend toward decreased HOMA (p = 0.09). Rosiglitazone significantly decreased C-peptide (p < 0.01) with a strong trend toward decreased fasting insulin (p = 0.05). Rosiglitazone reduced CRP compared with glyburide (p = 0.001), but no differences were observed between groups for ADMA or the markers of oxidative stress. Rosiglitazone significantly improved FMD (p < 0.05) with trends toward improvements in carotid artery distension (p = 0.099) and distensibility (p = 0.078). In conclusion, compared with glyburide, rosiglitazone improves endothelial function and CRP in patients with T2DM. These improvements are not associated with reductions in ADMA or markers of oxidative stress.

Key Words: asymmetric dimethylarginine • endothelial function • oxidative stress • rosiglitazone • type 2 diabetes mellitus

References

  • Marx N., Sukhova G., Murphy C., Libby P., Plutzky J. Macrophages in human atheroma contain PPARgamma: differentiation-dependent peroxisomal proliferator-activated receptor gamma(PPARgamma) expression and reduction of MMP-9 activity through PPARgamma activation in mononuclear phagocytes in vitro. Am J Pathol 1998; 153: 17—23.[Abstract/Free Full Text]
  • Raji A., Seely EW, Bekins SA, Williams GH, Simonson DC Rosiglitazone improves insulin sensitivity and lowers blood pressure in hypertensive patients. Diabetes Care 2003; 26: 172—78.[Abstract/Free Full Text]
  • Wang TD, Chen WJ, Lin JW, Chen MF, Lee YT Effects of rosiglitazone on endothelial function, C-reactive protein, and components of the metabolic syndrome in nondiabetic patients with the metabolic syndrome. Am J Cardiol 2004; 93: 362—65.[CrossRef][ISI][Medline] [Order article via Infotrieve]
  • Yosefy C., Magen E., Kiselevich A. et al. Rosiglitazone improves, while Glibenclamide worsens blood pressure control in treated hypertensive diabetic and dyslipidemic subjects via modulation of insulin resistance and sympathetic activity. J Cardiovasc Pharmacol 2004; 44: 215—22.[CrossRef][ISI][Medline] [Order article via Infotrieve]
  • Goldberg RB, Kendall DM, Deeg MA et al. A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia. Diabetes Care 2005; 28: 1547—54.[Abstract/Free Full Text]
  • Campia U., Matuskey LA, Panza JA Peroxisome proliferator-activated receptor-gamma activation with pioglitazone improves endothelium-dependent dilation in nondiabetic patients with major cardiovascular risk factors. Circulation 2006; 113: 867—75.[Abstract/Free Full Text]
  • Esposito K., Ciotola M., Carleo D. et al. Effect of rosiglitazone on endothelial function and inflammatory markers in patients with the metabolic syndrome. Diabetes Care 2006; 29: 1071—76.[Abstract/Free Full Text]
  • Langenfeld MR, Forst T., Hohberg C. et al. Pioglitazone decreases carotid intima-media thickness independently of glycemic control in patients with type 2 diabetes mellitus: results from a controlled randomized study. Circulation 2005; 111: 2525—31.[Abstract/Free Full Text]
  • Nakamura T., Matsuda T., Kawagoe Y. et al. Effect of pioglitazone on carotid intima-media thickness and arterial stiffness in type 2 diabetic nephropathy patients. Metabolism 2004; 53: 1382—86.[CrossRef][ISI][Medline] [Order article via Infotrieve]
  • Pfutzner A., Marx N., Lubben G. et al. Improvement of cardiovascular risk markers by pioglitazone is independent from glycemic control: results from the pioneer study. J Am Coll Cardiol 2005; 45: 1925—31.[Abstract/Free Full Text]
  • Pistrosch F., Passauer J., Fischer S., Fuecker K., Hanefeld M., Gross P. In type 2 diabetes, rosiglitazone therapy for insulin resistance ameliorates endothelial dysfunction independent of glucose control. Diabetes Care 2004; 27: 484—90.[Abstract/Free Full Text]
  • Choi D., Kim SK, Choi SH et al. Preventative effects of rosiglitazone on restenosis after coronary stent implantation in patients with type 2 diabetes. Diabetes Care 2004; 27: 2654—60.[Abstract/Free Full Text]
  • Marx N., Wohrle J., Nusser T. et al. Pioglitazone reduces neointima volume after coronary stent implantation. A randomized, placebo-controlled, double-blind trial in nondiabetic patients. Circulation 2005; 112: 2792—98.[Abstract/Free Full Text]
  • Nishio K., Sakurai M., Kusuyama T. et al. A randomized comparison of pioglitazone to inhibit restenosis after coronary stenting in patients with type 2 diabetes. Diabetes Care 2006; 29: 101—06.[Abstract/Free Full Text]
  • Haffner SM, Greenberg AS, Weston WM, Chen H., Williams K., Freed MI Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Circulation 2002; 106: 679—84.[Abstract/Free Full Text]
  • Samaha FF, Szapary PO, Iqbal N. et al. Effects of rosiglitazone on lipids, adipokines, and inflammatory markers in nondiabetic patients with low high-density lipoprotein cholesterol and metabolic syndrome. Arterioscler Thromb Vasc Biol 2006; 26: 624—30.[Abstract/Free Full Text]
  • Satoh N., Ogawa Y., Usui T. et al. Antiatherogenic effect of pioglitazone in type 2 diabetic patients irrespective of the responsiveness to its antidiabetic effect. Diabetes Care 2003; 26: 2493—99.[Abstract/Free Full Text]
  • Szapary PO, Bloedon LT, Samaha FF et al. Effects of pioglitazone on lipoproteins, inflammatory markers, and adipokines in nondiabetic patients with metabolic syndrome. Arterioscler Thromb Vasc Biol 2006; 26: 182—88.[Abstract/Free Full Text]
  • Marfella R., D'Amico M., Di FC et al. Increased activity of the ubiquitin-proteasome system in patients with symptomatic carotid disease is associated with enhanced inflammation and may destabilize the atherosclerotic plaque: effects of rosiglitazone treatment. J Am Coll Cardiol 2006; 47: 2444—55.[Abstract/Free Full Text]
  • Meisner F., Walcher D., Gizard F. et al. Effect of rosiglitazone treatment on plaque inflammation and collagen content in nondiabetic patients: data from a randomized placebo-controlled trial. Arterioscler Thromb Vasc Biol 2006; 26: 845—50.[Abstract/Free Full Text]
  • Dormandy JA, Charbonnel B., Eckland DJ et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglit Azone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005; 366: 1279—89.[CrossRef][ISI][Medline] [Order article via Infotrieve]
  • Hetzel J., Balletshofer B., Rittig K. et al. Rapid effects of rosiglitazone treatment on endothelial function and inflammatory bio-markers. Arterioscler Thromb Vasc Biol 2005; 25: 1804—809.[Abstract/Free Full Text]
  • McMahon GT, Plutzky J., Daher E., Bhattacharyya T., Grunberger G., DiCarli MF Effect of a peroxisome proliferator-activated receptor-gamma agonist on myocardial blood flow in type 2 diabetes. Diabetes Care 2005; 28: 1145—50.[Abstract/Free Full Text]
  • Sidhu JS, Cowan D., Kaski JC Effects of rosiglitazone on endothelial function in men with coronary artery disease without diabetes mellitus. Am J Cardiol 2004; 94: 151—56.[ISI][Medline] [Order article via Infotrieve]
  • Adachi T., Inoue M., Hara H., Maehata E., Suzuki S. Relationship of plasma extracellular-superoxide dismutase level with insulin resistance in type 2 diabetic patients. J Endocrinol 2004; 181: 413—17.[Abstract]
  • Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412—19.[CrossRef][ISI][Medline] [Order article via Infotrieve]
  • Dengel DR, Kelly AS, Olson TP, Kaiser DR, Dengel JL, Bank AJ Effects of weight loss on insulin sensitivity and arterial stiffness in overweight adults. Metabolism 2006; 55: 907—11.[CrossRef][ISI][Medline] [Order article via Infotrieve]
  • Kelly AS, Kaiser DR, Dengel DR, Bank AJ Comparison of B-mode and echo tracking methods of assessing flow-mediated dilation. Ultrasound Med Biol 2004; 30: 1447—49.[CrossRef][ISI][Medline] [Order article via Infotrieve]
  • Kaiser DR, Billups K., Mason C., Wetterling R., Lundberg JL, Bank AJ Impaired brachial artery endothelium-dependent and -independent vasodilation in men with erectile dysfunction and no other clinical cardiovascular disease. J Am Coll Cardiol 2004; 43: 179—84.[Abstract/Free Full Text]
  • Vallance P., Leone A., Calver A., Collier J., Moncada S. Endogenous dimethylarginine as an inhibitor of nitric oxide synthesis. J Cardiovasc Pharmacol 1992; 20(suppl 12): S60—S62.[ISI][Medline] [Order article via Infotrieve]
  • Stuhlinger MC, Abbasi F., Chu JW et al. Relationship between insulin resistance and an endogenous nitric oxide synthase inhibitor. JAMA 2002; 287: 1420—26.[Abstract/Free Full Text]
  • Wang TD, Chen WJ, Cheng WC, Lin JW, Chen MF, Lee YT Relation of improvement in endothelium-dependent flow-mediated vasodilation after rosiglitazone to changes in asymmetric dimethylarginine, endothelin-1, and C-reactive protein in nondiabetic patients with the metabolic syndrome. Am J Cardiol 2006; 98: 1057—62.[CrossRef][ISI][Medline] [Order article via Infotrieve]
  • Asagami T., Abbasi F., Stuelinger M. et al. Metformin treatment lowers asymmetric dimethylarginine concentrations in patients with type 2 diabetes. Metabolism 2002; 51: 843—46.[CrossRef][ISI][Medline] [Order article via Infotrieve]
  • Morrow JD Quantification of isoprostanes as indices of oxidant stress and the risk of atherosclerosis in humans. Arterioscler Thromb Vasc Biol 2005; 25: 279—86.[Abstract/Free Full Text]
  • Schwedhelm E., Bartling A., Lenzen H. et al. Urinary 8-iso-prostaglandin F2alpha as a risk marker in patients with coronary heart disease: a matched case—control study. Circulation 2004; 109: 843—48.[Abstract/Free Full Text]
  • Ceriello A. Controlling oxidative stress as a novel molecular approach to protecting the vascular wall in diabetes. Curr Opin Lipidol 2006; 17: 510—18.[ISI][Medline] [Order article via Infotrieve]
  • Home PD, Pocock SJ, Beck-Nielsen H. et al. Rosiglitazone evaluated for cardiovascular outcomes — an interim analysis. N Engl J Med 2007; 357: 28—38.[Abstract/Free Full Text]
  • Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007; 356: 2457—71.[Abstract/Free Full Text]

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?



This Article
Right arrow Abstract Freely available
Right arrow Free Full Text (Free PDF) Free
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kelly, A. S.
Right arrow Articles by Bank, A. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kelly, A. S.
Right arrow Articles by Bank, A. J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?